5 High Growth International Stocks to Buy

3. Genmab A/S (NASDAQ:GMAB)

Number of Hedge Fund Holders: 12

Quarterly Revenue Growth YoY as of December 30, 2022: 72.2%

Genmab A/S (NASDAQ:GMAB) was founded in 1999 and is headquartered in Copenhagen, Denmark. The company develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. On February 23, Genmab A/S (NASDAQ:GMAB) reported FY 2022 GAAP EPS of DKK83.65 and a revenue of DKK14.6 billion, up 72.2% year-over-year. Genmab A/S (NASDAQ:GMAB) expects its 2023 revenue to be in the range of DKK 14,600 million – 16,100 million, compared to DKK 14,595 million in 2022. It is one of the top high growth international stocks to monitor. 

On February 23, Danske Bank analyst Thomas Bowers upgraded Genmab A/S (NASDAQ:GMAB) to Buy from Hold with a DKK 3,200 price target.

According to Insider Monkey’s fourth quarter database, 12 hedge funds were bullish on Genmab A/S (NASDAQ:GMAB), and Ken Griffin’s Citadel Investment Group is the largest stakeholder of the company, with 401,154 shares worth $17 million. 

Artisan Partners made the following comment about Genmab A/S (NASDAQ:GMAB) in its Q4 2022 investor letter:

“Genmab A/S (NASDAQ:GMAB) is a developer of monoclonal antibody products for the treatment of life-threatening and debilitating diseases. Growth remains strong (+35% YoY in the most recent quarter) for Darzalex, the company’s leading therapy for multiple myeloma, and we continue to find Genmab’s new product pipeline as attractive. However, we trimmed the position based on valuation to support more compelling opportunities within biotech.”